Panelists discuss how recent regulatory approvals and innovative therapeutic mechanisms are expanding options for EGFR-positive non–small cell lung cancer (NSCLC). They explore the benefits of dual-targeting agents such as amivantamab, which simultaneously inhibits EGFR and MET, and next-generation tyrosine kinase inhibitors (TKIs) such as sunvozertinib that address resistance mutations. The discussion incorporates findings from recent studies, including FLAURA2, which demonstrated improved survival with osimertinib plus chemotherapy, balanced against higher toxicity. Panelists note how these new treatments and subcutaneous formulations are driving a shift toward more durable, mechanism-based, and patient-centered care strategies.
add a comment
